Efficacy and safety of fenofibrate or gemfibrozil on serum lipid profiles in Chinese patients with type IIb hyperlipidemia: A single-blind, randomized, and cross-over study

Chinese Medical Journal (Taipei)

Volumn 59, Issue 4, 1997, Pages 217-224

  Jen, Shu Long ^a   Chen, Jaw Wen ^b,c   Lee, Wen Lieng ^b,c   Wang, Shih Pu ^b,c  

^a TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cholesterol; Fenofibrate; High density lipoprotein (HDL); Low density lipoprotein (LDL); Triglyceride; Type IIb hyperlipidemia

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; FENOFIBRATE; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MALE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE;

ADULT; AGED; ANTILIPEMIC AGENTS; CROSS-OVER STUDIES; FEMALE; GEMFIBROZIL; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; PROCETOFEN; SINGLE-BLIND METHOD;

EID: 0030941734     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Beaumont JL, Carlson LA, Cooper GR, Fejfar Z, Fredrickson DS. Classification of hyperlipidemias and hyperlipoproteinemias. Bulletin of the World Health Organization 1970;43:891-915.
2. Balfour JA, McTavish D, Heel RC. Fenofibrate: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidemia. Drugs 1990;40:260-90.
3. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber T. High density lipoprotein as a protective factor against coronary artery disease: the Framingham Study. Am J Med 1977;62:707-14.
4. Knopp RH, Brown WV, Dujovne CA, Farquhar JW, Feldman EB, Goldberg AC. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 1987;83(suppl 5B):50-9.
5. Brown WV. Effects of fenofibrate on plasma lipids. Arteriosclerosis 1986;6:670-8.
6. Blane GF. Review of European clinical experience with fenofibrate. Cardiology 1989;76(suppl 1):1-13.
7. Brown WV. Fenofibrate, a third-generation fibric acid derivative. Am J Med 1987;83(suppl 5B):1-8.
8. Avogaro P, Bittolo BG, Belussi F, Pontoglio E, Cazzolato G. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinemic states. Atherosclerosis 1983;47:95-100.
9. Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type Ha or lib hyperlipidemia. Arch Intern Med 1994;154:441-9.
10. Persky VW, Dyer AR, Idris-Soven E, Stamler J, Shekille RB. Uric acid: a risk factor for coronary heart disease? Circulation 1979;59:969-77.
11. Chatrenet P, Regimbean C, Ramain JP, Penot J, Bruandet P. Chronic active cirrhogenic hepatitis induced by fenofibrate.Gastroenterol Clin Biol 1993;17:612-3.
12. Bravo ML, Azagra R, Aguye A, Freixas M. Acute hepatitis: an adverse reaction to fenofibrate treatment. Afencion Primaria 1992;10:697-8.